CIRCIO HOLDING ASA |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.12 NOK | -5.78% |
|
+4.95% | -70.56% |
| Apr. 25 | Circio Holding ASA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Apr. 17 | Circio Establishes In Vivo Proof-of-Concept for Circular RNA Platform | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | 148M 13.88M | Capitalization | 18.66M 1.75M |
|---|---|---|---|---|---|
| Net income 2024 * | -67M -6.29M | Net income 2025 * | 16M 1.5M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 67M 6.29M | Net cash position 2025 * | 132M 12.4M | EV / Sales 2025 * | -0.77 x |
| P/E ratio 2024 * |
-0.23
x | P/E ratio 2025 * |
0.29
x | Employees | 9 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 82.67% |
More Fundamentals
* Assessed data
More news
Latest transcript on Circio Holding ASA
More press releases
| 1 day | -6.67% | ||
| 1 week | +3.96% | ||
| Current month | -16.00% | ||
| 1 month | -19.85% | ||
| 3 months | -67.44% | ||
| 6 months | -73.75% | ||
| Current year | -70.83% |
1 week
2.10
2.25
1 month
1.993.00
Current year
1.998.10
1 year
1.9923.97
3 years
1.99288.00
5 years
1.99360.00
10 years
1.991 080.00
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 17-03-31 | |
Lubor Gaal
DFI | Director of Finance/CFO | 56 | 22-03-06 |
Thomas Hansen
CTO | Chief Tech/Sci/R&D Officer | - | 21-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Diane Mellett
BRD | Director/Board Member | 64 | 15-09-13 |
Thomas Falck
BRD | Director/Board Member | 58 | 22-04-20 |
| Director/Board Member | 77 | 15-06-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-21 | 2.12 | -5.78% | 6 472 |
| 24-05-16 | 2.25 | +2.74% | 35,524 |
| 24-05-15 | 2.19 | +8.42% | 16,557 |
| 24-05-14 | 2.02 | -7.76% | 78,862 |
Real-time Oslo Bors, May 21, 2024 at 05:26 am EDT
More quotes
Circio Holding ASA, formerly Targovax ASA, is a Norway-based company active within the healthcare sector. The Company is engaged in the biotechnology and develops ribonucleic acid (RNA) and immunotherapy medicines. The Company offers circular RNA (circRNA) platform to develop circRNA medicines for cancer, vaccines, protein replacement for genetic disorders and cell therapy. The circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA-based vectors that can be deployed for multiple purposes. Circios strategy is to develop circAde cancer medicines in-house and seek partnerships in other therapeutic areas to demonstrate the broad potential of the circVec platform and accelerate circRNA pipeline development. Circioâs second clinical program is an immunotherapy targeting KRAS driver mutations.
Calendar
2024-06-04
- Annual General Meeting
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
2.25
NOK
Average target price
12
NOK
Spread / Average Target
+433.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -70.83% | 1.75M | |
| +9.58% | 115B | |
| +12.41% | 107B | |
| -3.46% | 21.6B | |
| -12.38% | 22.31B | |
| -6.87% | 19.19B | |
| -3.35% | 18.23B | |
| -38.57% | 17.62B | |
| +7.51% | 14.26B | |
| +35.67% | 12.37B |
- Stock Market
- Equities
- TRVX Stock
